Skip to content

Compare medicines

Put up to three medicines side by side. Useful for alternatives in the same class, or for seeing how two very different treatments differ.

Attribute
In shortTargeted pill for EGFR-mutated lung cancer.Targeted pill that turned a deadly leukaemia into a manageable condition.
Body systemCancerCancer
Drug classTyrosine kinase inhibitorsTyrosine kinase inhibitors
SupplyPrescription onlyPrescription onlyWHO essential medicine
Main usesEGFR-mutated non-small cell lung cancer (advanced and after surgery)Chronic myeloid leukaemia, Philadelphia-positive ALL, Gastrointestinal stromal tumour (GIST)
How it worksBlocks a faulty growth switch in some lung cancers.Switches off the faulty protein that makes leukaemia cells grow.
Starts working——
Half-lifeAbout 48 hoursAbout 18 hours
Typical adult dose80 mg once a day.Usually 400 mg once a day with food.
FormsTabletTablet
Common side effectsDiarrhoea, Rash, Dry skin, Nail infectionsSwelling around the eyes, Muscle cramps, Nausea, Diarrhoea, Rash
Serious side effectsLung inflammation, QT prolongation, Heart failureFluid retention, Low blood counts, Liver injury, Heart failure (rare)
Don't take if——
Alcohol——
PregnancyUsually avoidedContraception needed.Usually avoidedEffective contraception needed.
Breastfeeding——
In use since20152001
Brand namesUnited States: TagrissoUnited Kingdom: TagrissoIndia: TagrissoUnited States: GleevecUnited Kingdom: GlivecIndia: Veenat, Imatib
Legal status——
ATC codeL01EB04L01EA01

Taken together

No interaction between these medicines is recorded in the atlas.

Open in the interaction checker